Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%

By Yahoo! Finance   |   1 year ago
Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%

Eli Lilly And Co announced positive Phase 2 results for muvalaplin, a potential treatment for high Lp(a) levels linked to heart disease. The study showed significant reductions in Lp(a) levels, meeting primary and secondary endpoints, with promising safety profiles.

Read More

Did you find this insightful?